Merck Group, a leading science and technology company, to complete the acquisition of the MAST (Modular Automated Sampling Technology) platform from Lonza.
Fresenius Kabi to enter an exclusive U.S. distribution agreement with Corvida Medical for the HALO Closed System Drug-Transfer Device.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4090
Published Date: May 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing use of antineoplastics for the treatment of cancer is estimated to boost market growth.
The market size of closed system transfer devices (CSTD) is anticipated to attain a CAGR of 15% over the forecast period, i.e., 2023-2035.
The high cost of implementation of CSTD is estimated to hamper the market growth.
North America is estimated to create notable growth opportunities for market growth over the forecast period.
The major players in the market are B. Braun Melsungen AG, ICU Medical, Inc., Equashield, LLC, Simplivia Healthcare Ltd., Corvida Medical, Inc., Caragen Ltd., Baxter International Inc., and Pfizer Inc.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by technology, end-user, type, and by region.
The membrane-to-membrane segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.